Entropy Neurodynamics (ASX: ENP, formerly Tryp Therapeutics) is a clinical-stage biotech developing psilocin therapies w/ psychotherapy for unmet medical needs.
Melbourne
Joined July 2020
- Tweets729
- Following186
- Followers1.4K
- Likes487
ICYMI: 📢 @Entropy_Neuro (#ASX: $ENP) secures South African patent for proprietary psilocin formulations through 2043
⚡ Strengthens TRP-8803's IP protection, supporting future licensing & strategic partnerships
#biotech #health
youtube.com/shorts/SVMj5KlyA…
ICYMI: 🔬Entropy Neurodynamics secured a South African patent for proprietary psilocin crystalline forms, strengthening the IP portfolio supporting TRP-8803. Protection extends to September 2043.
Read more: asx.api.cmfyapp.com/asx-rese…
#ASX $ENP #Biotech
From the @InvestorStream_ desk:
📢 @Entropy_Neuro (#ASX: $ENP) secures South African patent for proprietary psilocin formulations through 2043
⚡ Strengthens TRP-8803's IP protection, supporting future licensing & strategic partnerships
#biotech #health
youtube.com/shorts/SVMj5KlyA…
🔬Entropy Neurodynamics secured a South African patent for proprietary psilocin crystalline forms, strengthening the IP portfolio supporting TRP-8803. Protection extends to September 2043.
Read more: asx.api.cmfyapp.com/asx-rese…
#ASX $ENP #Biotech
ICYMI: A strong quarter for Entropy Neurodynamics $ENP
✅ 100% clinical response, 50% remission in Phase 2 BED study (6 patients)
✅ 72-patient, 8-indication study approved
✅ US clinical pathway advanced with UCSF
✅ BioCina manufacturing agreement
READ: asx.api.cmfyapp.com/asx-rese…
A strong quarter for Entropy Neurodynamics $ENP
✅ 100% clinical response, 50% remission in Phase 2 BED study (6 patients)
✅ 72-patient, 8-indication study approved
✅ US clinical pathway advanced with UCSF
✅ BioCina manufacturing agreement
READ: asx.api.cmfyapp.com/asx-rese…
ICYMI: Entropy (#ASX: $ENP) presented preliminary TRP-8803 data at ECNP: rapid, consistent psychedelic effects across 12 dosing sessions in six binge eating disorder patients, with no serious adverse events reported.
Read more: asx.api.cmfyapp.com/asx-rese… #biotech
Entropy (#ASX: $ENP) presented preliminary TRP-8803 data at ECNP: rapid, consistent psychedelic effects across 12 dosing sessions in six binge eating disorder patients, with no serious adverse events reported.
Read more: asx.api.cmfyapp.com/asx-rese… #biotech @ecnptweets
ICYMI: 📢 From the @InvestorStream_ desk:
@EntropyNeuro (#ASX: $ENP) cuts its TRP-8803 infusion from 140 to 60 minutes in its Phase 2 BED study
⚡ A key test of a more practical, scalable treatment model
▶️ youtube.com/shorts/kjvPx2g5k…
#Biotech $ENP.ax #ASXNews
ICYMI: Our first Cohort 2 patient completed a 60-minute TRP-8803 infusion in the Phase 2 binge eating disorder study and was safely discharged.
The cohort tests a shorter infusion, down from 140 minutes. Topline results expected by end-CY26.
asx.api.cmfyapp.com/asx-rese… #ASX $ENP
📢 From the @InvestorStream_ desk:
@EntropyNeuro (#ASX: $ENP) cuts its TRP-8803 infusion from 140 to 60 minutes in its Phase 2 BED study
⚡ A key test of a more practical, scalable treatment model
▶️ youtube.com/shorts/kjvPx2g5k…
#Biotech $ENP.ax #ASXNews
Our first Cohort 2 patient completed a 60-minute TRP-8803 infusion in the Phase 2 binge eating disorder study and was safely discharged.
The cohort tests a shorter infusion, down from 140 minutes. Topline results expected by end-CY26.
Read: asx.api.cmfyapp.com/asx-rese…
#ASX $ENP
ICYMI: 📎 Prenzler Group’s latest desk note on Entropy Neurodynamics (ASX: ENP) highlights TRP-8803’s 12-week binge eating disorder results, upcoming readouts and planned US depression trial.
READ MORE: mcusercontent.com/9e72b121f2…
#ENP #Biotech #ClinicalTrials
📎 Prenzler Group’s latest desk note on Entropy Neurodynamics (ASX: ENP) highlights TRP-8803’s 12-week binge eating disorder results, upcoming readouts and planned US depression trial.
READ MORE: mcusercontent.com/9e72b121f2…
#ENP #Biotech #ClinicalTrials
ICYMI via @StockheadAU: Tylah Tully chats with Prof Susan Rossell, principal investigator for @Entropy_Neuro binge eating disorder study, to discuss why psychedelic-assisted therapies are drawing growing attention. #ASX #Health $ENP
stockhead.com.au/stockhead-t…
📢 ICYMI: $ENP reports durable Phase 2 TRP-8803 results in treatment-resistant BED: all 6 patients maintained clinically meaningful improvement at 12 weeks, with weekly binge-eating episodes 73% below baseline.
READ MORE: asx.api.cmfyapp.com/asx-rese…
From the @InvestorStream_ desk:
📢 $ENP reports all 6 TRP-8803 BED patients maintained clinically meaningful improvement at 12 weeks
⚡ 50% recorded zero binge-eating episodes across 84 days, with weekly episodes 73% below baseline
📈 SP +2.5% | Vol ~1.06M #ASX #biotech
📢 $ENP reports durable Phase 2 TRP-8803 results in treatment-resistant BED: all 6 patients maintained clinically meaningful improvement at 12 weeks, with weekly binge-eating episodes 73% below baseline.
READ MORE: asx.api.cmfyapp.com/asx-rese…
ICYMI Annual Report: FY26 saw TRP-8803 enter Phase 2 BED studies. Post year-end, all 6 Cohort 1 patients responded clinically, 3 achieved remission, and a 72-patient, 8-disorder basket study gained ethics approval. announcements.asx.com.au/asx… #ASX $ENP
Annual Report: FY26 saw TRP-8803 enter Phase 2 BED studies. Post year-end, all 6 Cohort 1 patients responded clinically, 3 achieved remission, and a 72-patient, 8-disorder basket study gained ethics approval. announcements.asx.com.au/asx… #ASX $ENP
